HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Juan M Saavedra Selected Research

Glutamic Acid (Glutamate)

11/2020Candesartan could ameliorate the COVID-19 cytokine storm.
3/2016Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.
1/2016An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease.
4/2014Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARĪ³ activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Juan M Saavedra Research Topics

Disease

22Inflammation (Inflammations)
01/2021 - 06/2004
16Hypertension (High Blood Pressure)
01/2021 - 12/2003
9Brain Ischemia (Cerebral Ischemia)
01/2018 - 09/2002
7Brain Diseases (Brain Disorder)
03/2020 - 07/2012
7Stroke (Strokes)
03/2019 - 03/2003
7Encephalitis (Encephalitis, Rasmussen)
01/2018 - 01/2011
7Ischemia
01/2018 - 09/2002
6Traumatic Brain Injuries (Traumatic Brain Injury)
01/2017 - 11/2012
4COVID-19
11/2020 - 01/2020
4Neurodegenerative Diseases (Neurodegenerative Disease)
05/2019 - 11/2012
4Alzheimer Disease (Alzheimer's Disease)
03/2016 - 11/2012
3Neuroinflammatory Diseases
03/2022 - 11/2015
3Infarction (Infarctions)
12/2015 - 09/2002
3Stomach Ulcer (Gastric Ulcer)
06/2005 - 08/2003
2Insulin Resistance
01/2021 - 03/2020
2Substance-Related Disorders (Drug Abuse)
03/2020 - 06/2008
2Ischemic Stroke
01/2018 - 12/2015
2Cardiovascular Diseases (Cardiovascular Disease)
01/2016 - 11/2012
2Anxiety Disorders (Anxiety Disorder)
11/2012 - 06/2008
2Body Weight (Weight, Body)
03/2011 - 12/2006
1Dysbiosis
03/2022
1Cytokine Release Syndrome
11/2020
1Genomic Instability
03/2020
1Werner Syndrome (Werner's Syndrome)
03/2020
1Schizophrenia (Dementia Praecox)
03/2020
1Virus Diseases (Viral Diseases)
05/2019
1Neoplasm Metastasis (Metastasis)
03/2019
1Adenocarcinoma of Lung
03/2019
1Brain Infarction
01/2018
1Infections
01/2017
1Metabolic Brain Diseases (Encephalopathy, Metabolic)
01/2017
1Chronic Renal Insufficiency
03/2016
1Brain Injuries (Brain Injury)
11/2015
1Cognitive Dysfunction
11/2015
1Acute-Phase Reaction
10/2015
1Metabolic Syndrome (Dysmetabolic Syndrome X)
03/2015
1Central Nervous System Diseases (CNS Diseases)
11/2012
1Mood Disorders (Mood Disorder)
11/2012
1Acute Monocytic Leukemia (Acute Monoblastic Leukemia)
01/2012
1Migraine Disorders (Migraine)
04/2009
1Atrophy
09/2008
1Parkinson Disease (Parkinson's Disease)
09/2008
1Alcoholism (Alcohol Abuse)
06/2008
1Stab Wounds (Stab Wound)
07/2006
1Wounds and Injuries (Trauma)
07/2006

Drug/Important Bio-Agent (IBA)

26Angiotensin IIIBA
03/2020 - 09/2002
12candesartanIBA
11/2020 - 09/2002
10Angiotensin Receptor AntagonistsIBA
01/2021 - 01/2011
7Telmisartan (Micardis)FDA Link
05/2019 - 01/2012
5Therapeutic UsesIBA
01/2018 - 04/2014
4Amyloid (Amyloid Fibrils)IBA
03/2022 - 11/2012
4Glutamic Acid (Glutamate)FDA Link
11/2020 - 04/2014
4Proteins (Proteins, Gene)FDA Link
03/2020 - 03/2003
4Angiotensin II Type 1 Receptor BlockersIBA
11/2015 - 04/2014
4Messenger RNA (mRNA)IBA
06/2012 - 03/2003
3Neuroprotective AgentsIBA
01/2018 - 11/2012
3EndotoxinsIBA
07/2012 - 01/2011
3LipopolysaccharidesIBA
03/2011 - 10/2008
2Antihypertensive Agents (Antihypertensives)IBA
01/2020 - 10/2013
2Pharmaceutical PreparationsIBA
01/2018 - 01/2016
2Glucose (Dextrose)FDA LinkGeneric
01/2017 - 03/2016
2Angiotensin Receptors (Angiotensin II Receptor)IBA
11/2015 - 12/2009
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2005 - 08/2003
2Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
07/2004 - 08/2003
2Epinephrine (Adrenaline)FDA LinkGeneric
08/2003 - 05/2003
1SynucleinsIBA
03/2022
1Protein AggregatesIBA
03/2022
1ChemokinesIBA
11/2020
1CytokinesIBA
11/2020
1NF-kappa B (NF-kB)IBA
11/2020
1Mitogen-Activated Protein Kinase 14IBA
03/2020
1AminesIBA
03/2020
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
03/2020
1Interleukin-6 (Interleukin 6)IBA
03/2020
1PPAR gammaIBA
05/2019
1Long Noncoding RNAIBA
03/2019
1polydatinIBA
03/2019
1AMP-Activated Protein KinasesIBA
01/2018
1Virulence Factors (Pathogenicity Factors)IBA
01/2017
1NucleoproteinsIBA
01/2017
1Biomarkers (Surrogate Marker)IBA
03/2016
1totarolIBA
12/2015
1Nerve Growth Factors (Neurotrophins)IBA
11/2015
1ApolipoproteinsIBA
10/2015
1Valsartan (Vals)FDA Link
10/2013
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
12/2012
1GABA-A Receptors (GABA(A) Receptor)IBA
06/2012
1Interleukin-1beta (Interleukin 1 beta)IBA
05/2012
1Minocycline (Cyclops)FDA LinkGeneric
04/2012
1Substance PIBA
04/2009
1AngiotensinsIBA
06/2008
1Ethanol (Ethyl Alcohol)IBA
06/2008
1Adrenocorticotropic Hormone (ACTH)FDA Link
06/2008
1Hormones (Hormone)IBA
06/2008
1candesartan cilexetil (Amias)FDA Link
12/2006
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
10/2006
1beta Adrenergic ReceptorsIBA
10/2006
1CGP 42112AIBA
07/2006

Therapy/Procedure

7Therapeutics
01/2020 - 10/2006
1Caloric Restriction
03/2020